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ABSTRACT
There is a need for predictive biomarkers that identify non-
small-cell lung cancer (NSCLC) patients most likely to
respond to epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) treatment. There are
numerous potential candidates, although none has been
proven in prospective clinical trials. The EGFR gene copy
number evaluated by fluorescence in situ hybridisation
(FISH) has been highlighted as one of the most effective
markers for sensitivity to EGFR TKIs in large phase III,
randomised placebo-controlled trials and has been used in
clinical settings to assist physicians in defining the
therapeutic regimen. The EGFR FISH assay has technical
challenges and it is critical that detailed guidelines are
provided to help clinical laboratories in performing and
interpreting the test. Excellent assay reproducibility and
portability rates among laboratories are crucial to
guarantee that accurate clinical decisions can be made for
patients with NSCLC. This article discusses the consensus
outcomes of a global workshop convened to discuss key
technical issues and standardise reading strategies for the
EGFR FISH assay of NSCLC tumour tissue.
Lung cancer remains the leading cause of cancer-
related death worldwide.
1 The prognosis for
advanced non-small-cell lung cancer (NSCLC) is
poor
2 and global 5-year survival rates are low,
ranging between only 10% and 15%.
34Standard
chemotherapy for NSCLC has reached a plateau in
its therapeutic efficacy
56 ; however, novel targeted
agents that act on molecules in signalling path-
ways have emerged as effective agents in treating
NSCLC
7 and they have provided renewed opti-
mism for patients with advanced disease. The
epidermal growth factor receptor (EGFR) is a
tyrosine kinase (TK) receptor that is expressed in
40–80% of patients with NSCLC.
89 Due to the
important role of EGFR in cellular growth and
proliferation, it has been proposed as a target for
NSCLC therapy
10 and several EGFR inhibitors are
being evaluated as treatment options for patients
with advanced NSCLC.
11
The EGFR TK inhibitors (TKIs, eg, erlotinib
(Tarceva; OSI Pharmaceuticals, Inc, Melville, New
York, USA; Genentech, Inc, South San Francisco,
California, USA; and F Hoffmann-La Roche Ltd,
Basel, Switzerland) and gefitinib (Iressa;
AstraZeneca Pharmaceuticals, Wilmington,
Delaware, USA)) are further along in clinical
development for NSCLC treatment than other
EGFR-targeted therapies. Erlotinib is currently the
only approved EGFR TKI for advanced NSCLC
therapy in the USA and European Union; the
2-month survival advantage observed with erloti-
nib compared with placebo in the pivotal phase III
BR.21 trial led to its approval for the second-line/
third-line therapy of patients with advanced
disease.
12 While gefitinib is approved for use in
Japan, it was not approved by the US Food and
Drug Administration for the treatment of recur-
rent NSCLC because the pivotal ISEL (Iressa
Survival in Lung Cancer) trial failed to demonstrate
a significant increase in the overall survival (OS) of
patients treated with gefitinib compared with
placebo in this indication.
13 The impact of cetux-
imab (an anti-EGFR antibody; Erbitux, Imclone
Systems Inc, New York, USA) on the treatment of
NSCLC is not yet clear. In the large FLEX trial, the
cetuximab plus cisplatin/vinorelbine arm demon-
strated a significant survival advantage,
14 whereas
in the smaller BMS-099 trial a similar but not
significant trend was found in the cetuximab plus
carboplatin+taxane arm.
15
Strategies for patient selection using molecular
diagnostics have the potential to increase the
efficacy of these molecular-targeted therapies and
optimise response to treatment in patients with
advanced NSCLC. Research efforts are ongoing to
develop and validate laboratory tests for assess-
ment of positive and negative predictive markers of
treatment response and survival. Notably, no
predictive marker of survival benefit with anti-
EGFR treatment efficacy has been demonstrated
prospectively, although validation studies toward
this end are ongoing. EGFR protein expression
assessed by immunohistochemistry, EGFR gene
copy number by fluorescence in situ hybridisation
(FISH), and mutations in the EGFR or other
downstream genes have been under investigation
as potential biomarkers that may predict sensitiv-
ity to anti-EGFR therapy. Two large, randomised
clinical trials of EGFR TKI monotherapy in second-
line/third-line NSCLC have been retrospectively
analysed for biomarkers that may predict response
and survival benefit to EGFR TKIs: BR.21
16 17 and
ISEL.
18 Data from both trials supported EGFR FISH
status as a potential predictive marker of tumour
response and patient survival to TKIs. Recently, a
phase II trial in patients with advanced NSCLC
also demonstrated that cetuximab plus chemother-
apy improved progression-free survival (PFS) and
OS in EGFR FISH-positive patients compared with
those who were FISH-negative.
19 These results
suggest that an assay to determine EGFR FISH
status may be applicable for selection of patients
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these results is warranted before the use of the marker is
implemented for patient management.
The study by Cappuzzo et al
20 was the first to show that high
EGFR copy number correlated significantly with improved
survival in patients treated with gefitinib. NSCLC patients were
classified into six groups according to the ascending copy
number of the EGFR gene, and individuals with EGFR high
polysomy or gene amplification (defined as EGFR FISH-
positive) had a significantly higher response rate, and a
significantly longer time-to-progression (TTP) and survival than
patients with no EGFR gene gain (defined EGFR FISH-negative).
EGFR FISH status has since been investigated retrospectively in
numerous trials with conflicting impact on OS (table 1).
All studies used the LSI EGFR/CEP 7 probe set (Abbott
Molecular, Des Plaines, Illinois, USA).
In the single-arm TRUST study with erlotinib, EGFR FISH-
positive patients showed an improved OS,
21 in contrast EGFR
FISH-positive patients in the randomised studies INVITE
(gefitinib monotherapy),
22 INTEREST (gefitinib monother-
apy)
23–25 and TRIBUTE (erlotinib+chemotherapy)
26 demon-
strated no improved benefit in survival with EGFR TKI
treatment. Notably, in the TRIBUTE study, among EGFR
FISH-positive patients, the TTP was longer in patients who
received erlotinib, despite the lack of OS benefit. The variability
seen in the published clinical evidence for the predictive value of
the EGFR FISH assay in NSCLC could result from differences
between the studies (eg, different patient populations, different
study designs and treatment and control arms (TKI mono-
therapy versus placebo or TKI+chemotherapy versus che-
motherapy)), as well as differences in the methodologies used
by the various study laboratories for performing and interpret-
ing the assay. Additionally, there is no clear definition for the
scoring of atypical signals and/or gene clusters in the Colorado
scoring method and a lack of a precise method for calculation of
the EGFR ratio; this could lead to a different interpretation of
signals among different labs and across different studies. These
high technical and interpretive complexities encountered when
performing, reading and interpreting the FISH assay reinforce
the need for standardised testing procedures. Some recommen-
dations for the standardised application and interpretation of
molecular assays in NSCLC have been suggested for the clinical
trial setting.
27 In addition, preliminary laboratory performance
guidelines for assessment of the EGFR FISH assay in the
stratification of patients with NSCLC have been reported.
28
However, detailed guidelines for correctly performing and
interpreting the EGFR FISH assay are needed to ensure the high
reproducibility and portability between testing laboratories, as
these are crucial for the successful clinical application of the assay.
CONSENSUS GUIDELINES FOR ANALYSIS AND
INTERPRETATION OF THE EGFR FISH ASSAY
These consensus guidelines are the result of a global workshop
convened to discuss key technical issues and standardise reading
strategies for the EGFR FISH assay of NSCLC tumour tissue. All
laboratories should also comply with all guidelines required by
the regulatory agencies in their countries.
Sample preparation and storage guidelines
Pre-analytical variables can affect the final result of the EGFR
FISH assay. For consistently robust and reproducible results,
standardisation of the pre-analytical conditions and processes,
as well as those of the assay itself, and interpretation of results
are needed. Largely, the recommendations regarding pre-
analytical variables are similar to the recommended guidelines
for HER2 FISH testing in breast carcinoma.
29
Fixation and storage of tumour specimens
The duration of fixation and the type of fixative used are key
issues that could affect the viability of samples and modify
subsequent FISH results. Samples should be fixed for greater
than 6 h but no more than 48 h in 10% neutral buffered
formalin/4% neutral buffered formaldehyde. The date and
duration of fixation should be recorded for each specimen
whenever feasible. Bouin’s, mercury-containing fixatives and
any fixatives that would destroy DNA should be avoided.
Ideally, tumour samples should be stored as blocks (formalin
fixed, paraffin embedded) at room temperature, rather than as
cut tissue sections.
Selection of tumour specimens
Tumour content of the specimen should be confirmed in a
H&E-stained slide serial to the unstained sections prior to
performing subsequent steps of FISH assays or prior to sending
the sample to an external laboratory. It is preferable to use the
Table 1 EGFR FISH status and impact on survival in selected randomised NSCLC trials with EGFR TKIs
Study/author Treatment arm
No. of patients
with EGFR FISH
result
No. of patients with EGFR
FISH-positive status*
HR for survival in EGFR
FISH-positive patients{
Cut-off values for EGFR FISH-
positive status
BR.21/Tsao et al
16 17 Erlotinib (150 mg) versus
placebo
159 56 (45) 0.43 (0.004) High degrees of polysomy or
EGFR gene amplification using
Colorado scoring criteria
ISEL/Hirsch et al
18 Gefitinib (250 mg) versus
placebo
370 114 (31) 0.61 (0.067) High polysomy (>4 copies of
EGFR in >40% of cells) or EGFR
gene amplification
INVITE/Crino et al
22 Gefitinib (250 mg) versus
vinorelbine
158 54 (34) 2.88 NR
INTEREST/Kim et al
24 25 Gefitinib (250 mg) versus
docetaxel
374 174 (47) 1.09 (0.52) High polysomy (>4 copies of
EGFR in >40% of cells) or EGFR
gene amplification
TRIBUTE/Hirsch et al
26 Carboplatin/
paclitaxel+erlotinib (150 mg)
versus carboplatin/
paclitaxel+placebo
245 100 (41) 1.52 (0.083) High polysomy (>4 copies of
EGFR in >40% of cells) or EGFR
gene amplification
*Values in parentheses are percentages; {values in parentheses are p values.
EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridisation; HR, hazard ratio; NR, not reported in manuscript; NSCLC, non-small-cell lung cancer; TKI, tyrosine
kinase inhibitor.
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number of viable, morphologically intact tumour cells to fulfil
the scoring requirements (see below) and histopathological
representation of the patient’s tumour as a whole.
Sectioning of tissue
Positively charged slides should be used for mounting of tissue
sections in order to avoid detachment of the tissue. The
recommended thickness of tissue sections used for the EGFR
FISH assay is 4 mM (range 1 mM), and the sectioning date
should be recorded. If slides with sections are stored prior to
testing, the date of sectioning and section storage conditions
(room temperature, protected from light and humidity) should
also be noted.
EGFR FISH assay
Laboratories may follow the standard operating procedures that
have proved to be successful for formalin-fixed, paraffin-
embedded tissue sections in their settings for performing the
assay. Attention must be paid to particular steps in the protocol
that may affect probe penetration and hybridisation to target
DNA in order to optimise signal intensities. The deparaffinisa-
tion process must remove all traces of residual paraffin,
therefore the solvents should be changed for fresh solvents on
a regular and frequent basis according to the number of sections
being processed. Modifications in the protease digestion
protocol may be required for specific cases (eg, large surgical
specimens), and small biopsies may require different digestion
times, as well as freshly cut and previously stored slides.
Figure 1 Quality assessment of non-
small-cell lung cancer section subjected
to the epidermal growth factor receptor
fluorescence in situ hybridisation assay.
(A, B) Specimens acceptable for analysis,
showing well-defined nuclear morphology
and excellent intensity of the fluorescent
signals. (C–F) Specimens not acceptable
for analysis because there are missing
areas of nuclear chromatin (C), they show
large autofluorescent structures
obscuring the probe signals (D), they have
poorly defined nuclear borders (E), or the
intensity of the fluorescent signals is poor
(F).
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may require longer digestion times than those with non-
mucinous or more delicate stromal matrix.
After hybridisation, sealing the coverslips in place with rubber
cement, finger nail polish, etc, is not necessary; however large
coverslips should be used to avoid mixing of immersion oil and
the 49,6-diamidino-2-phenylindole (DAPI)/anti-fade mounting
medium. The hybridised slides should be stored in the dark at
220uCt o+4uC until analyses and review are completed.
Microscope analysis is recommended to be performed within
1 week of the assay in order to guarantee the optimal
fluorescence intensity.
Reading the EGFR FISH assay
Qualifications of personnel reading EGFR FISH
A properly trained reader who has undergone training in FISH
should analyse the slides. The reader also should have had
training on the pathological appearance of lung cancer, and
should have easy access to assistance from an expert lung
pathologist. The competency of all technical personnel reading
and interpreting the results should be evaluated at least
annually and continuous training should be ensured. The
participation of the laboratory in quality assurance/quality
control programmes is highly advised, as recommended in the
HER2 testing guidelines.
29
Quality assessment of the EGFR FISH specimen
Once the assay control slides have been assessed and passed
quality criteria, the quality of each tumour specimen must be
assessed to determine its acceptability for analysis. At least 50%
of tumour cells have to pass the assessment test fulfilling
the following criteria prior to the actual reading and scoring.
(a) Verification of integrity of the tumour nuclear morphology
using the DAPI filter. Within adequate specimens, the chroma-
tin of tumour cells should be well defined and non-disrupted
(fig 1A, B). The preparation should not be undertreated to the
point of preventing clear identification of the nuclear border, or
overtreated with chromatin missing from nuclear areas.
Tumour nuclei should not be covered by a cloudy yellowish
layer or obscured by autofluorescent structures. Examples of
specimens that do not pass quality assessment are illustrated in
fig 1C–F. (b) Verification of the quality of the hybridisation in
tumour and non-tumour cells using single-pass and double-pass
interference filters. Green signals (CEP7) should be bright,
compact (occasionally slightly stringy or diffuse) oval shapes,
and red (EGFR) signals should be bright, small round shapes
(fig 1A, B). The CEP7 signal is usually larger and brighter than
the EGFR red signal and they are commonly adjacent. Signals
should not be fuzzy, very patchy or blotchy. Representative
images of those conditions are provided in fig 2A–D.
(c) Confirmation that the background of the specimen appears
dark and free of fluorescent particles or haziness under
inspection with single-pass and double-pass interference filters.
Selection of tumour areas and tumour nuclei
Using H&E-guided microscopy prior to FISH reading, the
histopathological features of the tumour should be assessed,
including identification and characterisation of invasive tumour
Figure 2 Inadequate signal quality in
non-small-cell lung cancer sections for
the epidermal growth factor receptor
fluorescence in situ hybridisation assay
that direct to subjective judgment. (A)
Cross-hybridisation of the CEP7 probe
with multiple unspecific targets
generating multiple faint green signals.
(B) Particulate background noise showing
up as large red fluorescent spots. (C) Very
stringy green signals. (D) Blotchy and
patchy red signals, while the green
signals are faint.
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presence of inflammatory or necrotic areas, which should be
avoided.The tumour foci shouldalways be identifiedon the H&E-
stained slide by a lung pathologist, independently of whether the
FISH analysis is to be performed by a pathologist or not.
Five areas representative of the histopathological features of
the invasive part of the tumour must be selected. The selected
areas are identified in the FISH slide with the DAPI filter, and
within each area an average of 10 nuclei should be selected for
analysis, for a total of 50 counted nuclei.
Selection of tumour nuclei for reading should be performed
using high-magnification objectives according to the following
criteria: (a) with the DAPI filter, identify tumour nuclei of
average size or larger, with non-disrupted chromatin and non-
overlapping borders (as illustrated in fig 3); (b) with the single
green, single red or dual red/green filters, confirm that selected
cells carry at least one copy of each EGFR and CEP7 signal.
The areas and level of heterogeneity in the tissue should be
noted,ifheterogeneityispresent.Tumoursmaybeheterogeneous
in their susceptibility to protease (eg, depending on extracellular
matrix composition) and the quality of the EGFR signal may be
different among these areas.
Enumeration of signals
The number of EGFR and CEP7 signals in the selected nuclei
should be counted with single-pass interference filters (one filter
for each probe wavelength) at 660 to 6100 magnification and
recorded separately. In the signal enumeration, there are special
situations that require careful attention, such as when signals
are split, paired, or in triplets or clusters (figs 4 and 5). Doublet
or triplet spots that are physically linked, ie, touching or linked
by a thread, or adjacent (with a gap smaller than the diameter of
the largest signal), are counted as one signal only. However,
spots that are adjacent but separated by at least the diameter of
the largest signal are counted as separate signals. The maximum
number of signals to be counted in a single cluster is 15. If
signals are .15 the cluster is considered as innumerable and
reported as ‘‘16’’. A number is still required for calculation of the
overall EGFR/CEP7 ratio, but counting in this range becomes
increasingly difficult.
Due to the variety of mechanisms of EGFR amplification and
clustering patterns noted in NSCLC samples, recommendation
is provided in table 2 on how to score and interpret clusters of
EGFR and CEP7 signals in these unique cases. Raw data should
always be carefully recorded and stored, as they may be found
to be useful in future studies.
Number of readers for EGFR FISH
In its implementation at the University of Colorado (see
Interpretation of the EGFR FISH results according to the
Colorado scoring criteria), the EGFR FISH assay was scored by
two independent readers, with a third reader involved when
there was discordance between the first and second. Because of
increased demand for efficiently testing large numbers of
patients, a study was performed to establish a FISH evaluation
procedure that would minimise the number of readers and
reduce the number of specimens requiring multiple readers
(L Morrison, personal communication 2008). The study utilised
a mathematical approach to identify an equivocal range to
determine if the sample was FISH positive or FISH negative.
Based on the results of this study, the consensus recommenda-
tion was to set the high end of the equivocal range as 40% cells
with >4 signals, above which the first reader’s result classifies
the specimen as EGFR FISH-positive. The low end was set at
25% of cells with >4 signals, below which the first reader’s
result classifies the specimen as EGFR FISH-negative. If the
score of the first reader was within the equivocal or borderline
range of .25% to ,40% of cells with >4 signals, then a second
reader, blinded to the results of the first reader, was required. If
Figure 3 Selection of tumour cells to score. (A) High-magnification
field under 49,6-diamidino-2-phenylindole (DAPI) filter showing seven
nuclei that qualify to be scored (indicated by asterisks) since they have
average or larger size, non-disrupted chromatin, and intact and non-
overlapping borders. (B) The same field with merged blue, red and green
channels showing that all the selected nuclei (indicated by arrows) carry
at least one signal for each probe. Therefore, all seven nuclei qualify for
scoring.
Figure 4 Guide for signal enumeration when epidermal growth factor
receptor spots show up as doublets, triplets or clusters.
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concluded as FISH positive, and as FISH negative otherwise.
Interpretation of the EGFR FISH results according to the Colorado
scoring criteria
A scheme for classifying NSCLC tumours as EGFR FISH-
positive and FISH-negative was developed at the University of
Colorado and has been used in multiple clinical studies.
20 28
EGFR FISH-positive
(A) Specimens that have >40% of cells displaying >4 copies of
the EGFR signal.
(B) Specimens that display EGFR gene amplification, defined
according to one of the following criteria: (a) an EGFR to CEP7
ratio >2 over all scored nuclei and calculated using the sum of
EGFR divided by the sum of CEP7 when mean CEP7 per cell is
>2 copies; (b) the presence of gene cluster (>4 spots) in >10%
of tumour cells; (c) at least 15 copies of the EGFR signals in
>10% of tumour cells.
EGFR FISH-negative
Specimens that do not display gene amplification according to
the criteria defined above and with ,40% of cells displaying >4
copies of the EGFR signal.
Future directions and conclusions
There are several areas that need further investigation. For
instance, the application of the Colorado scoring system
requires adaptation and subsequent validation for cytological
specimens and smears since those specimens include whole cells
and do not have truncated nuclei as in the tissue sections.
The unique biology of advanced-stage NSCLC also pose
difficulties associated with tumour heterogeneity that might get
unaccounted for in small biopsies or even in very large
Figure 5 Examples of challenging
scenarios for signal enumeration. (A)
Nuclei with doublet and triplet spots
counted as one signal each plus ‘‘paired’’
spots counted as two signals. (B–D)
Nuclei with epidermal growth factor
receptor (EGFR) gene amplification
represented by clusters of signals
probably due to HSR (homogeneously
staining region). Clusters may include few
spots (minimum of four spots, illustrated
in B), intermediate (C) or very high
numbers of spots (D). (E) Nuclei with
EGFR gene amplification represented as
numerous double minutes. (F) Nuclei with
clusters of EGFR and CEP7 signals. In
each nucleus, signals are enumerated as
precisely as possible focusing up and
down. If more than 15 signals are counted
(which is a common finding in specimens
with large clusters and double minutes)
report ‘‘16’’ in the analysis worksheet.
Review
J Clin Pathol 2009;62:970–977. doi:10.1136/jcp.2009.066548 975specimens. Potential differences may exist in the genomic status
of EGFR in pretreated versus untreated patients and the vast
majority of information currently available was generated in
diagnostic specimens from patients who had not received prior
treatment. The predictive value of EGFR FISH in primary
tumours compared with their corresponding metastases is
another issue that requires confirmation in future clinical trials.
Yet to be determined are the potential benefits or drawbacks of
the FISH technology versus the related methods of chromogenic
in situ hybridisation/silver in situ hybridisation for evaluation
of the copy number of the EGFR gene in NSCLC.
Last, the development of robust quality assurance pro-
grammes and regular proficiency and competency assessment
of laboratories performing these assays are necessary to improve
the consistency of assay performance and interpretation. It is
our intention that these guidelines will provide a tool to help
the clinical laboratories involved with the EGFR FISH test in
NSCLC to accomplish these goals.
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signals
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thoroughly and
calculate the
indexes. If number
of signals is .15,
write ‘‘16’’
.2 Classify as positive
(GA) if EGFR/CEP7
ratio >2 or if clusters
of EGFR signals are
present in >10% cells
Small clusters of EGFR
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thoroughly and
calculate the
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.2t o,1i f
high level of
aneusomy 7
is present
Classify as positive
(GA) if EGFR/CEP7
ratio >2 or if clusters
of EGFR signals are
present in >10% cells
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EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridisation; GA,
EGFR gene amplification.
Take-home messages
c Data from epidermal growth factor receptor (EGFR)
fluorescence in situ hybridisation (FISH) assessment in clinical
trials vary greatly. This may be due to different patient
populations, different study designs, and variability in the
methods used by different laboratories for reading and
interpreting FISH.
c Excellent assay reproducibility is crucial to ensure that
accurate clinical decisions are made for patients with non-
small-cell lung cancer, therefore guidelines are critical for
clinical laboratories performing and interpreting EGFR FISH
assays.
c The guidelines summarised in this manuscript provide
information on the inclusion/exclusion criteria, reading and
scoring of slides, assessment of signal clusters and
assessment of borderline cases.
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Review
976 J Clin Pathol 2009;62:970–977. doi:10.1136/jcp.2009.06654816. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical
predictors of outcome. N Engl J Med 2005;353:133–44.
17. Zhu CQ, da Cunha SG, Ding K, et al. Role of KRAS and EGFR as biomarkers of
response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study
BR.21. J Clin Oncol 2008;26:4268–75.
18. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with
gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung
cancer. J Clin Oncol 2006;24:5034–42.
19. Hirsch FR, Herbst RS, Olsen C, et al. Increased EGFR gene copy number
detected by fluorescent in situ hybridization predicts outcome in non-small-cell
lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol
2008;26:3351–7.
20. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and
protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst
2005;97:643–55.
21. Schneider C-P, Heigener D, Schott-von-Romer K, et al. EGFR-related tumor markers
and clinical outcomes with Erlotinib in NSCLC: an analysis of patients from German
centers in the TRUST Study. J Thorac Oncol 2008;12:1446–53.
22. Crino L, Cappuzzo F, Zatloukal P, et al. Gefitinib versus vinorelbine in chemotherapy-
naive elderly patients with advanced non-small-cell lung cancer (INVITE): a
randomized, phase II study. J Clin Oncol 2008;26:4253–60.
23. Douillard J, Hirsh V, Mok T, et al. Molecular and clinical subgroup analyses from a
phase III trial comparing gefitinib with docetaxel in previously treated non-small cell
lung cancer (INTEREST) [abstract]. J Clin Oncol 2008;26(Suppl):no. 8001.
24. Douillard J-Y, Kim ES, Hirsh V, et al. Gefitinib (IRESSA) versus docetaxel in patients
with locally advanced or metastatic non-small cell lung cancer pre-treated with
platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST).
J Thorac Oncol 2007;2:S305–6.
25. Kim ES, Hirsh V, Mok T, et al. Gefitinib versusdocetaxel in previously treated non-small-
cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809–18.
26. Hirsch FR, Varella-Garcia M, Dziadziuszko R, et al. Fluorescence in situ hybridization
subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and
paclitaxel in non-small cell lung cancer. Clin Cancer Res 2008;14:6317–23.
27. Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth
factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group:
standardization for use in the clinical trial setting. J Clin Oncol 2008;26:983–94.
28. Varella-Garcia M. Stratification of non-small cell lung cancer patients for therapy
with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ
hybridization assay. Diagn Pathol 2006;1:19.
29. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/
College of American Pathologists guideline recommendations for human epidermal
growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118–45.
BMJ Masterclasses
BMJ Masterclasses are educational meetings designed specifically to meet the learning needs of
doctors. They help doctors keep up to date with the latest evidence and recent guidelines in major
clinical areas, enabling them to use the latest evidence to make better decisions. The latest evidence,
recent guidelines and best practice are delivered in an interactive and informative manner by leading
experts. The speakers are specifically chosen as highly-skilled communicators who can authoritatively
enthuse the audience and interpret the latest research and guidelines into practical tips for busy
doctors. BMJ Masterclasses have proved a huge hit with clinicians, with many saying they have
influenced their clinical practice.
http://masterclasses.bmj.com/
Review
J Clin Pathol 2009;62:970–977. doi:10.1136/jcp.2009.066548 977